The acquisition of Modulus Therapeutics' cell therapy assets, including CAR and switch receptor libraries, directly enhances Ginkgo Bioworks' capabilities in cell programming and biosecurity. This strategic move is likely to be viewed positively by investors, as it could open up new opportunities and markets for Ginkgo Bioworks, potentially leading to an increase in its stock price in the short term.